These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 25578603

  • 1. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
    Li Z, Liu Q, Li C, Zong X, Bai J, Wu Y, Lan X, Yu G, Zhang Y.
    Mol Cell Endocrinol; 2015 Feb 15; 402():64-71. PubMed ID: 25578603
    [Abstract] [Full Text] [Related]

  • 2. Role of TGF-β1/Smad3-mediated fibrosis in drug resistance mechanism of prolactinoma.
    Hu B, Mao Z, Jiang X, He D, Wang Z, Wang X, Zhu Y, Wang H.
    Brain Res; 2018 Nov 01; 1698():204-212. PubMed ID: 30055965
    [Abstract] [Full Text] [Related]

  • 3. miR-93-5p targets Smad7 to regulate the transforming growth factor-β1/Smad3 pathway and mediate fibrosis in drug-resistant prolactinoma.
    Hu B, Mao Z, Du Q, Jiang X, Wang Z, Xiao Z, Zhu D, Wang X, Zhu Y, Wang H.
    Brain Res Bull; 2019 Jul 01; 149():21-31. PubMed ID: 30946881
    [Abstract] [Full Text] [Related]

  • 4. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
    Wang S, Wang A, Zhang Y, Zhu K, Wang X, Chen Y, Wu J.
    BMC Endocr Disord; 2021 Nov 23; 21(1):235. PubMed ID: 34814904
    [Abstract] [Full Text] [Related]

  • 5. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
    Cristina C, Díaz-Torga GS, Goya RG, Kakar SS, Perez-Millán MI, Passos VQ, Giannella-Neto D, Bronstein MD, Becu-Villalobos D.
    Mol Cancer; 2007 Jan 12; 6():4. PubMed ID: 17222350
    [Abstract] [Full Text] [Related]

  • 6. Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists.
    Passos VQ, Fortes MA, Giannella-Neto D, Bronstein MD.
    Neuroendocrinology; 2009 Jan 12; 89(2):163-70. PubMed ID: 18791324
    [Abstract] [Full Text] [Related]

  • 7. Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas.
    Cai L, Leng ZG, Guo YH, Lin SJ, Wu ZR, Su ZP, Lu JL, Wei LF, Zhuge QC, Jin K, Wu ZB.
    Endocrine; 2016 Jun 12; 52(3):641-51. PubMed ID: 26662185
    [Abstract] [Full Text] [Related]

  • 8. Active and total transforming growth factor-β1 are differentially regulated by dopamine and estradiol in the pituitary.
    Recouvreux MV, Guida MC, Rifkin DB, Becu-Villalobos D, Díaz-Torga G.
    Endocrinology; 2011 Jul 12; 152(7):2722-30. PubMed ID: 21521749
    [Abstract] [Full Text] [Related]

  • 9. Filamin-A is essential for dopamine d2 receptor expression and signaling in tumorous lactotrophs.
    Peverelli E, Mantovani G, Vitali E, Elli FM, Olgiati L, Ferrero S, Laws ER, Della Mina P, Villa A, Beck-Peccoz P, Spada A, Lania AG.
    J Clin Endocrinol Metab; 2012 Mar 12; 97(3):967-77. PubMed ID: 22259062
    [Abstract] [Full Text] [Related]

  • 10. The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas.
    Recouvreux MV, Camilletti MA, Rifkin DB, Díaz-Torga G.
    J Endocrinol; 2016 Mar 12; 228(3):R73-83. PubMed ID: 26698564
    [Abstract] [Full Text] [Related]

  • 11. Sex differences in the pituitary transforming growth factor-β1 system: studies in a model of resistant prolactinomas.
    Recouvreux MV, Lapyckyj L, Camilletti MA, Guida MC, Ornstein A, Rifkin DB, Becu-Villalobos D, Díaz-Torga G.
    Endocrinology; 2013 Nov 12; 154(11):4192-205. PubMed ID: 24008346
    [Abstract] [Full Text] [Related]

  • 12. Suppression of MMQ cells by fulvestrant: possible mechanism of action and potential application for bromocriptine-resistant prolactinomas.
    Bai J, Gui S, Zhang Y.
    J Clin Neurosci; 2013 May 12; 20(5):721-5. PubMed ID: 23523357
    [Abstract] [Full Text] [Related]

  • 13. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
    Gao H, Wang F, Lan X, Li C, Feng J, Bai J, Cao L, Gui S, Hong L, Zhang Y.
    BMC Cancer; 2015 Apr 12; 15():272. PubMed ID: 25884948
    [Abstract] [Full Text] [Related]

  • 14. Thrombospondin-1 and transforming growth factor-β1 levels in prolactinoma and their clinical significance.
    Jiang M, Mou CZ, Han T, Wang M, Yang W.
    J Int Med Res; 2012 Apr 12; 40(4):1284-94. PubMed ID: 22971480
    [Abstract] [Full Text] [Related]

  • 15. Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas.
    Caccavelli L, Morange-Ramos I, Kordon C, Jaquet P, Enjalbert A.
    J Neuroendocrinol; 1996 Oct 12; 8(10):737-46. PubMed ID: 8910802
    [Abstract] [Full Text] [Related]

  • 16. MicroRNAs in Dopamine Agonist-Resistant Prolactinoma.
    Wan X, Yan Z, Tan Z, Cai Z, Qi Y, Lu L, Xu Y, Chen J, Lei T.
    Neuroendocrinology; 2022 Oct 12; 112(5):417-426. PubMed ID: 34034260
    [Abstract] [Full Text] [Related]

  • 17. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
    Luque GM, Perez-Millán MI, Ornstein AM, Cristina C, Becu-Villalobos D.
    J Pharmacol Exp Ther; 2011 Jun 12; 337(3):766-74. PubMed ID: 21406548
    [Abstract] [Full Text] [Related]

  • 18. Resistance to bromocriptine in prolactinomas.
    Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A.
    J Clin Endocrinol Metab; 1989 Sep 12; 69(3):500-9. PubMed ID: 2760167
    [Abstract] [Full Text] [Related]

  • 19. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
    Fusco A, Gunz G, Jaquet P, Dufour H, Germanetti AL, Culler MD, Barlier A, Saveanu A.
    Eur J Endocrinol; 2008 May 12; 158(5):595-603. PubMed ID: 18426817
    [Abstract] [Full Text] [Related]

  • 20. Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas.
    Xiao Z, Yang X, Zhang K, Liu Z, Shao Z, Song C, Wang X, Li Z.
    Int J Med Sci; 2020 May 12; 17(18):3174-3189. PubMed ID: 33173437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.